moclobemide has been researched along with Chronic Disease in 2 studies
Moclobemide: A reversible inhibitor of monoamine oxidase type A; (RIMA); (see MONOAMINE OXIDASE INHIBITORS) that has antidepressive properties.
moclobemide : A member of the class of benzamides that is benzamide substituted by a chloro group at position 4 and a 2-(morpholin-4-yl)ethyl group at the nitrogen atom. It acts as a reversible monoamine oxidase inhibitor and is used in the treatment of depression.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The primary objectives of this multicenter study were to determine the efficacy and safety of moclobemide, a selective reversible inhibitor of monoamino oxidase A, as drug treatment in DSM-III-R panic disorder with and without agoraphobia." | 9.09 | The efficacy and safety of moclobemide compared to clomipramine in the treatment of panic disorder. ( Dahl, AA; Krüger, MB, 1999) |
| "This trial aimed to study moclobemide, a reversible, Type-A selective monoamine oxidase inhibitor, in patients with chronic neuropathic pain." | 9.08 | Moclobemide in chronic neuropathic pain: preliminary case reports. ( Busch, AF; Fawcett, JP; Jones, D; Menkes, DB, 1995) |
| "The primary objectives of this multicenter study were to determine the efficacy and safety of moclobemide, a selective reversible inhibitor of monoamino oxidase A, as drug treatment in DSM-III-R panic disorder with and without agoraphobia." | 5.09 | The efficacy and safety of moclobemide compared to clomipramine in the treatment of panic disorder. ( Dahl, AA; Krüger, MB, 1999) |
| "This trial aimed to study moclobemide, a reversible, Type-A selective monoamine oxidase inhibitor, in patients with chronic neuropathic pain." | 5.08 | Moclobemide in chronic neuropathic pain: preliminary case reports. ( Busch, AF; Fawcett, JP; Jones, D; Menkes, DB, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Menkes, DB | 1 |
| Fawcett, JP | 1 |
| Busch, AF | 1 |
| Jones, D | 1 |
| Krüger, MB | 1 |
| Dahl, AA | 1 |
2 trials available for moclobemide and Chronic Disease
| Article | Year |
|---|---|
Moclobemide in chronic neuropathic pain: preliminary case reports.
Topics: Adult; Aged; Analgesics; Benzamides; Chronic Disease; Female; Humans; Male; Middle Aged; Moclobemide | 1995 |
The efficacy and safety of moclobemide compared to clomipramine in the treatment of panic disorder.
Topics: Adult; Aged; Benzamides; Chi-Square Distribution; Chronic Disease; Clomipramine; Female; Humans; Mal | 1999 |